Status:
COMPLETED
Long Term Follow-up of HPV Vaccine in HIV (CTN 236)
Lead Sponsor:
University of British Columbia
Collaborating Sponsors:
CIHR Canadian HIV Trials Network
Women's Health Research Institute of British Columbia
Conditions:
Cervical Cancer
Human Papillomavirus Infection
Eligibility:
FEMALE
11-60 years
Brief Summary
The purpose of this extension study is to determine whether HPV antibody levels in HIV-positive girls and women will decline more rapidly and more significantly than in HIV-negative girls and women an...
Detailed Description
Study hypothesis: HPV antibody levels in HIV-positive girls and women will decline more rapidly and more significantly than in HIV-negative girls and women and that this decline will be determined by ...
Eligibility Criteria
Inclusion
- Enrolled in CTN 236 study, phase 1
- Able to give fully informed consent or assent
Exclusion
- Did not receive at least one vaccination via CTN 236, phase 1
- Cannot provide fully informed consent or assent
Key Trial Info
Start Date :
June 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 30 2021
Estimated Enrollment :
241 Patients enrolled
Trial Details
Trial ID
NCT06915779
Start Date
June 1 2015
End Date
March 30 2021
Last Update
April 8 2025
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Oak Tree Clinic, BC Women's Hospital & Health Centre
Vancouver, British Columbia, Canada, V6H 3N1
2
AIDS Research Program & the John Ruedy Immunodeficience Clinic, St. Paul's Hospital
Vancouver, British Columbia, Canada, V6Z 1Y6
3
Hamilton Health Sciences
Hamilton, Ontario, Canada, L8S 1A4
4
Infection & Immunology Clinic, Hotel Dieu
Kingston, Ontario, Canada, K7L 5G2